S&P 500   3,946.11 (-0.07%)
DOW   32,070.36 (-0.11%)
QQQ   309.61 (-0.05%)
AAPL   159.29 (+0.23%)
MSFT   278.70 (+0.37%)
META   204.75 (+0.23%)
GOOGL   104.87 (-0.69%)
AMZN   97.61 (-1.11%)
TSLA   189.02 (-1.66%)
NVDA   265.53 (-2.35%)
NIO   8.94 (-3.56%)
BABA   86.48 (-0.05%)
AMD   97.53 (-2.74%)
T   18.52 (+0.33%)
F   11.43 (+0.09%)
MU   60.62 (-1.17%)
CGC   1.92 (+0.26%)
GE   90.78 (-0.88%)
DIS   93.66 (-2.26%)
AMC   4.47 (+0.00%)
PFE   40.25 (+0.17%)
PYPL   73.35 (+1.09%)
NFLX   325.82 (+1.70%)
S&P 500   3,946.11 (-0.07%)
DOW   32,070.36 (-0.11%)
QQQ   309.61 (-0.05%)
AAPL   159.29 (+0.23%)
MSFT   278.70 (+0.37%)
META   204.75 (+0.23%)
GOOGL   104.87 (-0.69%)
AMZN   97.61 (-1.11%)
TSLA   189.02 (-1.66%)
NVDA   265.53 (-2.35%)
NIO   8.94 (-3.56%)
BABA   86.48 (-0.05%)
AMD   97.53 (-2.74%)
T   18.52 (+0.33%)
F   11.43 (+0.09%)
MU   60.62 (-1.17%)
CGC   1.92 (+0.26%)
GE   90.78 (-0.88%)
DIS   93.66 (-2.26%)
AMC   4.47 (+0.00%)
PFE   40.25 (+0.17%)
PYPL   73.35 (+1.09%)
NFLX   325.82 (+1.70%)
S&P 500   3,946.11 (-0.07%)
DOW   32,070.36 (-0.11%)
QQQ   309.61 (-0.05%)
AAPL   159.29 (+0.23%)
MSFT   278.70 (+0.37%)
META   204.75 (+0.23%)
GOOGL   104.87 (-0.69%)
AMZN   97.61 (-1.11%)
TSLA   189.02 (-1.66%)
NVDA   265.53 (-2.35%)
NIO   8.94 (-3.56%)
BABA   86.48 (-0.05%)
AMD   97.53 (-2.74%)
T   18.52 (+0.33%)
F   11.43 (+0.09%)
MU   60.62 (-1.17%)
CGC   1.92 (+0.26%)
GE   90.78 (-0.88%)
DIS   93.66 (-2.26%)
AMC   4.47 (+0.00%)
PFE   40.25 (+0.17%)
PYPL   73.35 (+1.09%)
NFLX   325.82 (+1.70%)
S&P 500   3,946.11 (-0.07%)
DOW   32,070.36 (-0.11%)
QQQ   309.61 (-0.05%)
AAPL   159.29 (+0.23%)
MSFT   278.70 (+0.37%)
META   204.75 (+0.23%)
GOOGL   104.87 (-0.69%)
AMZN   97.61 (-1.11%)
TSLA   189.02 (-1.66%)
NVDA   265.53 (-2.35%)
NIO   8.94 (-3.56%)
BABA   86.48 (-0.05%)
AMD   97.53 (-2.74%)
T   18.52 (+0.33%)
F   11.43 (+0.09%)
MU   60.62 (-1.17%)
CGC   1.92 (+0.26%)
GE   90.78 (-0.88%)
DIS   93.66 (-2.26%)
AMC   4.47 (+0.00%)
PFE   40.25 (+0.17%)
PYPL   73.35 (+1.09%)
NFLX   325.82 (+1.70%)
NASDAQ:PCVX

Vaxcyte - PCVX News Today

$37.70
-0.18 (-0.48%)
(As of 03/24/2023 01:45 PM ET)
Add
Compare
Today's Range
$37.35
$37.95
50-Day Range
$37.08
$46.89
52-Week Range
$17.44
$49.31
Volume
155,175 shs
Average Volume
659,038 shs
Market Capitalization
$3.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$64.83
Get Vaxcyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter.


PCVX Media Mentions By Week

PCVX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PCVX
News Sentiment

0.58

0.35

Average
Medical
News Sentiment

PCVX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PCVX Articles
This Week

0

1

PCVX Articles
Average Week

SourceHeadline
finance.yahoo.com logoVaxcyte, Inc. (NASDAQ:PCVX) Q4 2022 Earnings Call Transcript
finance.yahoo.com - March 13 at 4:55 AM
finanznachrichten.de logoVaxcyte, Inc.: Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
finanznachrichten.de - March 1 at 8:25 AM
finance.yahoo.com logoVaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
finance.yahoo.com - March 1 at 8:25 AM
msn.com logoVaxcyte GAAP EPS of -$3.44 misses by $0.11
msn.com - March 1 at 8:25 AM
markets.businessinsider.com logoNeedham Keeps Their Buy Rating on Vaxcyte (PCVX)
markets.businessinsider.com - March 1 at 8:25 AM
benzinga.com logoPreview: Vaxcyte's Earnings
benzinga.com - February 24 at 4:00 PM
finance.yahoo.com logoVaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
finance.yahoo.com - February 21 at 11:08 AM
finance.yahoo.com logoVaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
finance.yahoo.com - February 16 at 7:22 PM
finance.yahoo.com logoVaxcyte to Present at the SVB Securities Global Biopharma Conference
finance.yahoo.com - February 7 at 8:49 PM
seekingalpha.com logoVaxcyte: Behind The Recent Rally
seekingalpha.com - January 16 at 7:51 AM
finance.yahoo.com logoThis Pneumococcal Vaccine Player Is The Top Pick For 2023 For This Analyst
finance.yahoo.com - January 3 at 5:39 PM
finance.yahoo.com logoSutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract
finance.yahoo.com - December 20 at 5:58 PM
technews.tmcnet.com logoVaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update
technews.tmcnet.com - November 8 at 6:31 PM
seekingalpha.com logoVaxcyte Has A Bright Future Ahead
seekingalpha.com - November 2 at 3:24 PM
finance.yahoo.com logoVaxcyte, Inc.'s (NASDAQ:PCVX) large institutional owners must be happy as stock continues to impress, up 111% over the past week
finance.yahoo.com - October 30 at 6:49 PM
finance.yahoo.com logoWhy Shares of Vaxcyte Rose 110.7% This Week
finance.yahoo.com - October 29 at 1:56 PM
benzinga.com logoVaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
benzinga.com - October 28 at 6:41 PM
finance.yahoo.com logoVaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - October 28 at 6:41 PM
247wallst.com logoVaxcyte (PCVX) Has Rallied 70% This Week on Trial Results. Is There More Upside?
247wallst.com - October 26 at 5:21 PM
finance.yahoo.com logoVaxcyte Announces Pricing of $600 Million Public Offering
finance.yahoo.com - October 26 at 2:18 AM
finance.yahoo.com logoVaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
finance.yahoo.com - October 25 at 11:03 AM
finance.yahoo.com logoVaccine developer Vaxcyte stock soars on results of experimental pneumonia jab
finance.yahoo.com - October 25 at 11:03 AM
finance.yahoo.com logoRecent Price Trend in Vaxcyte, Inc. (PCVX) is Your Friend, Here's Why
finance.yahoo.com - October 25 at 11:03 AM
msn.com logoHow Is The Market Feeling About Vaxcyte?
msn.com - October 24 at 12:49 PM
seekingalpha.com logoVaxcyte climbs 38% after proof-of-concept data for pneumococcal vaccine
seekingalpha.com - October 24 at 12:49 PM
thestreet.com logoBill Gates' Big Vaccine Bet Might Beat Pfizer
thestreet.com - October 24 at 12:49 PM
markets.businessinsider.com logoVaxcyte Shares Are Soaring: Here's Why
markets.businessinsider.com - October 24 at 12:49 PM
finance.yahoo.com logoVaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults
finance.yahoo.com - October 23 at 8:49 PM
finance.yahoo.com logoVaxcyte Expands Executive Leadership Team with Key Appointments
finance.yahoo.com - October 11 at 8:32 PM
nasdaq.com logoVaxcyte (PCVX) Shares Cross Below 200 DMA
nasdaq.com - October 4 at 3:48 PM
markets.businessinsider.com logoNeedham Reaffirms Their Buy Rating on Vaxcyte (PCVX)
markets.businessinsider.com - September 28 at 10:47 AM
markets.businessinsider.com logoVaxcyte Completes Enrolment In Mid-Stage Pneumococcal Disease Study, Sees Top-line Data In H1 2013
markets.businessinsider.com - September 6 at 6:33 PM
finance.yahoo.com logoVaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older
finance.yahoo.com - September 6 at 6:33 PM
finance.yahoo.com logoWe're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
finance.yahoo.com - August 15 at 7:09 AM
seekingalpha.com logoVaxcyte (PCVX) Investor Presentation - Slideshow
seekingalpha.com - August 13 at 7:13 PM
finance.yahoo.com logoVaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update
finance.yahoo.com - August 8 at 6:56 PM
seekingalpha.com logoVaxcyte wins FDA’s Fast Track designation for pneumococcal vaccine candidate
seekingalpha.com - August 4 at 1:03 PM
finance.yahoo.com logoVaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs
finance.yahoo.com - August 4 at 1:02 PM
finance.yahoo.com logoVaxcyte (PCVX) Completes Enrollment in Pneumococcal Disease Study
finance.yahoo.com - July 14 at 2:37 PM
markets.businessinsider.com logoVaxcyte Concludes Enrolment In Mid-Stage Pneumococcal Disease Study
markets.businessinsider.com - July 12 at 8:39 PM
finance.yahoo.com logoVaxcyte to Present at the Jefferies Healthcare Conference
finance.yahoo.com - June 2 at 7:14 PM
nasdaq.com logoPCVX Makes Bullish Cross Above Critical Moving Average
nasdaq.com - May 13 at 3:24 PM
finance.yahoo.com logoVaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update
finance.yahoo.com - May 9 at 6:37 PM
finance.yahoo.com logoCould The Vaxcyte, Inc. (NASDAQ:PCVX) Ownership Structure Tell Us Something Useful?
finance.yahoo.com - May 4 at 2:33 PM
nz.finance.yahoo.com logoVaxcyte to Participate in Upcoming Investor Conferences in May
nz.finance.yahoo.com - May 3 at 9:48 AM
finance.yahoo.com logoVaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 5 at 1:17 PM
finance.yahoo.com logoVaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults
finance.yahoo.com - April 4 at 11:41 AM
finance.yahoo.com logoCompanies Like Vaxcyte (NASDAQ:PCVX) Are In A Position To Invest In Growth
finance.yahoo.com - March 8 at 8:28 AM
finance.yahoo.com logoVaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
finance.yahoo.com - February 28 at 5:43 PM
seekingalpha.com logoVaxcyte doses first patients in phase 1/2 trial of pneumonia vaccine
seekingalpha.com - February 24 at 9:22 AM
Get Vaxcyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:PCVX) was last updated on 3/24/2023 by MarketBeat.com Staff